Boston Scientific (NYSE:BSX) Announces Earnings Results

Boston Scientific (NYSE:BSX) released its quarterly earnings data on Wednesday. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.78 by $0.02, FiscalAI reports. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The firm had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. During the same quarter in the prior year, the company posted $0.70 earnings per share. The business’s revenue was up 15.9% on a year-over-year basis.

Here are the key takeaways from Boston Scientific’s conference call:

• Boston Scientific beat 2025 guidance — Q4 revenue of $5.286B (+15.9% reported), FY revenue of $20.074B (+19.9%), Q4 adjusted EPS $0.80 and FY adjusted EPS $3.06 (+22%), with free cash flow of $3.659B (↑38%).
• 2026 outlook guides to full-year organic growth of 10%–11%, adjusted EPS $3.43–$3.49 (12%–14% growth), and 50–75 bps of operating margin expansion, reaffirming the 2026–2028 long‑range targets.
• EP and Watchman are key growth drivers — EP organic growth was 35% in Q4 (73% FY) driven by PFA adoption (~70% of US AF cases), and Watchman grew 29% in Q4; the upcoming Champion trial data at ACC could materially expand Watchman’s indication if positive.
• Near‑term operational headwinds include a product removal for certain Axios sizes and the discontinuation of Acclarent, which the company expects to create a ~150 bps drag on early‑2026 growth and to depress Endo/Urology performance in H1.
• Strategic M&A and healthy balance sheet — closed Nalu, announced Valencia and Penumbra deals to expand adjacencies, strong free cash flow and a 1.9x gross debt leverage ratio with major rating agencies affirming ratings.

Boston Scientific Trading Down 12.6%

Shares of BSX opened at $80.26 on Wednesday. The stock has a market capitalization of $118.98 billion, a P/E ratio of 43.46, a PEG ratio of 1.63 and a beta of 0.67. The firm has a fifty day simple moving average of $94.89 and a two-hundred day simple moving average of $99.29. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47. Boston Scientific has a twelve month low of $85.98 and a twelve month high of $109.50.

Insider Buying and Selling at Boston Scientific

In other news, Director Ellen M. Zane sold 12,891 shares of the business’s stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the sale, the director owned 24,134 shares in the company, valued at approximately $2,371,889.52. The trade was a 34.82% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction on Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the sale, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,396,580. This represents a 42.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 191,105 shares of company stock valued at $18,067,697. 0.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Boston Scientific

Several hedge funds have recently bought and sold shares of the stock. FWL Investment Management LLC bought a new stake in Boston Scientific during the second quarter valued at about $26,000. Pin Oak Investment Advisors Inc. purchased a new position in Boston Scientific during the 3rd quarter worth approximately $41,000. Johnson Financial Group Inc. grew its stake in shares of Boston Scientific by 196.4% during the 3rd quarter. Johnson Financial Group Inc. now owns 735 shares of the medical equipment provider’s stock worth $72,000 after purchasing an additional 487 shares during the period. Seldon Capital LP acquired a new position in shares of Boston Scientific in the 2nd quarter valued at $208,000. Finally, Victory Financial Group LLC boosted its stake in shares of Boston Scientific by 14.3% during the 3rd quarter. Victory Financial Group LLC now owns 2,216 shares of the medical equipment provider’s stock worth $216,000 after acquiring an additional 278 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Barclays decreased their price target on Boston Scientific from $136.00 to $124.00 and set an “overweight” rating for the company in a report on Tuesday. BTIG Research reiterated a “buy” rating and issued a $132.00 target price on shares of Boston Scientific in a research note on Friday, November 21st. Evercore ISI set a $112.00 target price on shares of Boston Scientific in a report on Monday, January 5th. UBS Group restated a “buy” rating on shares of Boston Scientific in a report on Wednesday, December 17th. Finally, Wells Fargo & Company upped their price objective on shares of Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, Boston Scientific has a consensus rating of “Moderate Buy” and an average price target of $123.26.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q4 beat and healthy top-line growth — BSX reported $0.80 EPS (vs. $0.78 consensus) and net sales of $5.286 billion, up ~15.9% year-over-year, demonstrating continued demand across its businesses. Boston Scientific announces results for fourth quarter and full year 2025
• Positive Sentiment: Analyst backing remains — several firms maintain buy/overweight views and some have raised targets, which supports longer-term sentiment if guidance proves conservative. Boston Scientific Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street’s Most Accurate Analysts
• Neutral Sentiment: Company materials posted — the official press release and slide deck are available for investors who want to dig into segment performance and management commentary. View Press Release
• Neutral Sentiment: Industry context — analysts note medical-products demand is mixed heading into 2026, which may mute upside even if BSX executes. 4 Medical Product Stocks to Watch From a Challenging Industry (Revised)
• Negative Sentiment: Cautious 2026 guidance — management issued a modest revenue-growth outlook and profit guidance below some Street expectations, which analysts and the market flagged as underwhelming and drove a sharp premarket selloff. Boston Scientific shares slide on cautious 2026 revenue forecast
• Negative Sentiment: Market reaction and commentary — coverage notes the Q4 beat but highlights the disappointing outlook as the primary reason for the share decline. Boston Scientific Earnings Beat Expectations. Why the Stock Is Down Sharply.
• Negative Sentiment: Insider selling — CEO Michael Mahoney disclosed a sale of 160,901 shares, which some investors view negatively even though insiders often sell for diversification or tax reasons. Insider Selling: Boston Scientific (NYSE:BSX) CEO Sells 160,901 Shares of Stock

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.